We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+20.27%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$169M
AUM Growth
+$22.7M
Cap. Flow
+$90.8M
Cap. Flow %
53.77%
Top 10 Hldgs %
87.24%
Holding
26
New
3
Increased
5
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$119M
2
EPZM
Epizyme, Inc
EPZM
+$11.4M
3
RGLS
Regulus Therapeutics
RGLS
+$7.78M
4
NVET
Nexvet Biopharma plc Ordinary Shares
NVET
+$6.7M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$2.55M

Top Sells

Rank Stock Value
1
UAM
Universal American Corp
UAM
+$27.8M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$6.45M
3
SAGE
Sage Therapeutics
SAGE
+$5.29M
4
PRQR icon
ProQR Therapeutics
PRQR
+$3.75M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 83.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
1
Larimar Therapeutics
LRMR
$416M
$56.5M 33.47%
292,621
+250,940
+602% +$119M
OREX
2
DELISTED
Orexigen Therapeutics, Inc.
OREX
$32.9M 19.48%
420,005
+18,238
+5% +$1.13M
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$14.2M 8.4%
754,806
+553,000
+274% +$11.4M
ASPX
4
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$7.52M 4.46%
75,000
-96,824
-56% -$6.45M
RGLS
5
DELISTED
Regulus Therapeutics
RGLS
$7.28M 4.31%
+3,581
New +$7.78M
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
$6.58M 3.9%
210,067
-10,000
-5% -$290K
NVET
7
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$5.69M 3.37%
+708,332
New +$6.7M
JUNO
8
DELISTED
Juno Therapeutics, Inc.
JUNO
$5.55M 3.29%
91,575
– –
QTNT
9
DELISTED
Quotient Limited Ordinary Shares
QTNT
$5.55M 3.29%
8,163
-28
-0.3% -$17.7K
SCYX icon
10
SCYNEXIS
SCYX
$37M
$5.5M 3.26%
8,287
– –
BDSI
11
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.7M 2.79%
447,878
+54,195
+14% +$740K
ALDR
12
DELISTED
Alder Biopharmaceuticals
ALDR
$4.54M 2.69%
157,131
-87,869
-36% -$2.41M
AGRX
13
DELISTED
Agile Therapeutics
AGRX
$4.26M 2.52%
230
-37
-14% -$648K
TTOO
14
DELISTED
T2 Biosystems, Inc
TTOO
$3.62M 2.14%
47
+1
+2% +$92.8K
SGMO
15
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.59M 1.53%
+165,000
New +$2.55M
RXDX
16
DELISTED
Ignyta, Inc.
RXDX
$1.84M 1.09%
185,220
-89,780
-33% -$672K
PRQR icon
17
ProQR Therapeutics
PRQR
$243M
– –
-173,067
Closed -$3.75M
SAGE
18
DELISTED
Sage Therapeutics
SAGE
– –
-144,569
Closed -$5.29M
SINT icon
19
SiNtx Technologies
SINT
$8.9M
– –
0
– -$180K
BLCM
20
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-10,500
Closed -$2.42M
UAM
21
DELISTED
Universal American Corp
UAM
– –
-3,000,000
Closed -$27.8M
BDSI
22
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-170,000
Closed -$2.04M
BDSI
23
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-100,000
Closed -$1.2M
OREX
24
CALL
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-25,150
Closed -$1.52M
OREX
25
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-10,000
Closed -$606K
1
2

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q1 2015 Portfolio in Review

As of Q1 2015, Foresite Capital Management II held 26 positions worth $169M, up 16% from $146M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Foresite Capital Management II deployed $90.8M of net new capital in Q1 2015, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Regulus Therapeutics: 3,581 shares worth $7.28M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 75% a quarter earlier.

On the sell side, the largest reduction was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $6.45M trimmed.

  • Foresite Capital Management II's largest Q1 2015 buy was Regulus Therapeutics: 3,581 shares worth $7.28M.
  • Foresite Capital Management II added most to Larimar Therapeutics in Q1 2015, an estimated $119M increase.
  • Foresite Capital Management II's biggest Q1 2015 reduction was AUSPEX PHARMACEUTICALS INC COM STK (DE), cutting an estimated $6.45M.
  • Foresite Capital Management II fully exited Universal American Corp in Q1 2015, selling an estimated $27.8M.
  • Foresite Capital Management II's ten largest holdings make up 87% of its $169M portfolio in Q1 2015.
  • Foresite Capital Management II opened 3 new positions and closed 9 in Q1 2015.
  • Foresite Capital Management II's portfolio value rose 16% quarter-over-quarter to $169M.

Based on Foresite Capital Management II's 13F filing for Q1 2015, filed 5 May 2015.